Does Mylan’s nebivolol + candesartan have an active patent?
The provided information does not include any patent identifiers, jurisdictions, or expiry dates for a “Mylan nebivolol candesartan” product. Without those details, the specific patent status and expiration can’t be determined.
If you share any one of the following, I can help pinpoint the relevant patent record and the likely expiry window:
- the exact product name/strength (e.g., tablet mg values),
- country (US, EU/UK, Canada, etc.),
- the label/ANDA or application number (if listed),
- or the patent number(s) you’ve seen referenced.
What patents usually cover a nebivolol + candesartan combination product?
For a fixed-dose combination like nebivolol + candesartan, patent coverage commonly comes from several different layers:
- composition-of-matter patents (covering the drug substances),
- formulation or manufacturing patents (how the combination is made or formulated),
- combination-treatment patents (using the two drugs together for a therapeutic purpose),
- and regulatory exclusivities (for example, data or market exclusivity) that can affect market entry even after some patents expire.
Which of these applies to the specific Mylan product depends entirely on the jurisdiction and the exact patent family.
When would a biosimilar-style “early entry” be possible?
Fixed-dose generic competition for small-molecule combinations typically turns on:
- whether patents covering the combination (or its method of use) are still listed/active, and
- whether any regulatory exclusivities still block approval or marketing.
Whether “early entry” is possible before all barriers clear depends on the remaining patent landscape for that exact combination product in the relevant country.
How to find the exact patent expiry for this specific combo (fast)
To locate the correct patents and expiry dates, the most reliable approach is:
1. Identify the specific approved combination product (include strength and country).
2. Pull the product’s reference to listed patents (in markets like the US, this is tied to the FDA’s Orange Book; in the EU/UK it’s different but still traceable).
3. Match the patent family to the combination formulation or indication being protected.
4. Check each patent’s expiration date and any extensions (and whether there are active litigation stays).
If you tell me the country (e.g., US vs EU) and the product strength, I can guide you to the specific database fields to check and what to look for.
What if you mean “Mylan brand vs Mylan ANDA”?
Sometimes people refer to the company name (Mylan) but the actual patent listings track a specific application or marketing authorization holder. Patent expiry and listed protections can differ between:
- brand companies’ originator products,
- Mylan’s specific generic submission,
- and later label changes or manufacturing site changes.
Sharing the exact product name as written on the package or the approval record removes that ambiguity.
What I need from you to answer the expiry precisely
Reply with:
- Country/jurisdiction (US/EU/UK/Canada/etc.)
- Product strength (nebivolol mg + candesartan mg)
- Whether you mean brand or a generic entry (if you know the ANDA/MA number, even better)
Then I can help you determine the specific patent(s) covering that nebivolol + candesartan combination and the likely expiry timeline.